MIMasanori Isobe

Masanori Isobe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masanori Isobe has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer

    by Mika Okazawa-Sakai, Takao Fujisawa, Tatsuyuki Chiyoda, Hiroshi Yagi, Ichinosuke Hyodo, Shogen Boku, Yoh Hayasaki, Masanori Isobe, Daisuke Shintani, Kosei Hasegawa, et al.

    Okazawa-Sakai M, et al. J Gynecol Oncol. 2027 ;38:e11. https://doi.org/10.3802/jgo.2027.38.e11


  • Factors Associated With Junior Residents' Choice of the Obstetrics and Gynecology Specialty: A Longitudinal Survey Based on 2025 Career Decisions

    by Koichiro Mori, Hiroaki Komatsu, Kazuki Sakaguchi, Mihoko Dofutsu, Masanori Isobe, Fuminori Taniguchi

    Aim: In Japan, the chronic shortage of obstetric–gynecologists exists in reality. To tackle the issue, we aim to identify the factors that promote or discourage junior residents' choice of the obstetrics‐gynecology (Ob/Gyn) specialty. Methods: We conducted a questionnaire survey of junior residents at the Summer School (SS) in 2023 and the Plus One Project 2 (POP2) in 2024 (preparatory educational events). One hundred and twenty‐two and 179 junior residents responded, respectively. In 2025, they decided whether to specialize in Ob/Gyn. We collected anonymized data on their decisions. Using the data, as a longitudinal study, we conducted a logistic regression analysis to examine how their preferences regarding working conditions are associated with their decisions. Results: There are several significant findings. First, those who consider the workplace's urban location more important are more likely to choose the Ob/Gyn specialty, according to the SS data. Second, concerns about the risk of lawsuits, fewer deliveries in the workplace, and low income prevent them from specializing in Ob/Gyn, according to the SS data. Third, those who consider annual income more important are more likely to choose the Ob/Gyn specialty, according to the POP2 data. Fourth, those who think that a sufficiently small number of night shifts is more important are less likely to specialize in Ob/Gyn, according to the POP2 data. Conclusion: The findings are provisional. However, after further data collection and analysis updates, this study may inform what should be done to increase the number of Ob/Gyn specialists in Japan.


  • Open Access

    Essential Kampo Formulas for General Clinicians Managing Female‐Specific Conditions: A Nationwide Survey of Obstetricians and Gynecologists in Japan

    by Takashi Takeda, Masanori Isobe, Takeshi Nagamatsu, Akitoshi Nakashma, Masatoshi Saito, Fusanori Yotsumoto

    Background: Although female‐specific conditions are frequently encountered in general clinical practice, nonspecialist physicians may have limited preparedness to manage these conditions. Therefore, Kampo medicine may be a practical therapeutic option in these settings. Aim: To identify Kampo formulas that are considered essential for general clinicians managing female‐specific conditions through a nationwide survey of obstetricians and gynecologists (OB/GYNs) in Japan. Methods: An anonymous web‐based questionnaire was administered among members of the Obstetrics and Gynecology Kampo Research Group between May and September 2025. The respondents selected up to eight Kampo formulas that were considered essential. Recommendation frequencies were analyzed, and the eight most frequently recommended formulas were defined as essential Kampo formulas. Associations with physician characteristics were examined using logistic regression and correspondence analyses. Results: Thirty Kampo formulas were used. The recommendation frequencies showed a nonuniform distribution, with endorsements concentrated among a limited number of formulas. Eight formulas, Kamishoyosan , Keishibukuryogan , Tokishakuyakusan , Goreisan , Yokukansan , Hangekobokuto , Hochuekkito , and Kamikihito , were identified as essential. Recommendation patterns were consistent across physicians' backgrounds, although minor differences were observed according to sex and clinical experience. Conclusions: A core set of Kampo formulas commonly recommended by OB/GYNs was identified, providing a practical foundation for clinical education and the implementation of Kampo medicine by general clinicians managing female‐specific conditions.

  • Medical Education Research in Japanese Obstetrics and Gynecology, 2014–2024: A Bibliometric Analysis

    by Kyosuke Kamijo, Yudai Kondo, Kota Sakaguchi, Masanori Isobe, Takashi Watari

    Aim: To describe the characteristics of medical education research in Japanese obstetrics and gynecology and identify gaps in themes, target populations, and patterns of international collaboration. Methods: We conducted a bibliometric review of English‐language articles indexed in PubMed from January 2014 to December 2024. We included peer‐reviewed original articles, reviews, and letters whose first author was an obstetrics and gynecology professional affiliated with a Japanese institution and whose primary focus was education of medical students, junior/senior residents, or attending physicians. Two reviewers independently screened records and extracted publication characteristics including publication trends, research themes, target populations, and international co‐authorship. Annual trends were assessed with the Mann–Kendall test and quantified using the Theil–Sen slope. Results: Of 61 records screened, 28 articles met inclusion criteria: 21 original articles, one review, and six letters or commentaries. The number of publications increased over time; however, the annual trend was not statistically significant (0.38 articles per year; p = 0.065). Surgical skills training (32.1%) and simulation‐based education (21.4%) were the most frequent themes. Senior residents were the most commonly studied population (82.1%), followed by attending physicians (46.4%), junior residents (21.4%), and medical students (17.9%). No article reported international co‐authorship. Conclusions: Medical education research output in Japanese obstetrics and gynecology was modest and concentrated on surgical skills training and simulation‐based education for senior residents, with minimal attention to earlier learner stages, nontechnical competencies, or international collaboration. These baseline data may inform strategic investment in broader educational themes, target populations, and partnerships.

  • Open Access

    CT- and MR Imaging–based Radiomics Approach to Differentiating Ovarian Mature and Immature Teratomas: Can MR Imaging–based Radiomics Predict the Histological Grade of Immature Teratomas?

    by Takahide Maeda, Hiroki Kato, Tatsuro Furui, Masanori Isobe, Tomotaka Kawamura, Hironori Nishibori, Masaya Kawaguchi, Yoshifumi Noda, Abdelazim Elsayed Elhelaly, Hirohiko Imai, et al.

    Purpose: This study aimed to evaluate CT- and MRI-based radiomic features of ovarian mature and immature teratomas (MTs and ITs) and to investigate the differences between low- and high-grade ITs.Methods: A total of 41 patients aged ≤ 30 years with histopathologically confirmed ovarian MT and 23 patients with ovarian IT who underwent preoperative MRI were included. Among them, 51 (31 MTs and 20 ITs) underwent preoperative CT. We investigated the differences in visual findings by radiologists and radiomics analysis not only between MTs and ITs but also between low- (grade 1) and high-grade (grades 2–3) ITs.Results: Multiple CT and MRI findings, along with radiomic features, showed significant differences between MTs and ITs (P < 0.05). Although the maximum diameter of nodular fat was greater in low-grade ITs than in high-grade ITs (P < 0.05), no other visual CT or MRI findings showed significant differences between low- and high-grade ITs. In contrast, several MRI-based radiomic features derived from fat-suppressed T1-weighted images, along with selected CT-based radiomic features, showed significant differences between low- and high-grade ITs (P < 0.05).Conclusion: Visual assessments by radiologists and radiomics analysis effectively distinguished MTs from ITs. However, differentiating between low- and high-grade ITs using visual assessment alone was difficult. Radiomics analysis—particularly MRI-based features from fat-suppressed T1-weighted images—showed potential as a noninvasive approach for grading ITs, although further validation is required.

  • Open Access

    Correction to: Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial

    by Kyoko Kikuno, Ryuta Asada, Takuma Ishihara, Ken-Ichirou Morishige, Kenro Chikazawa, Tatsuro Furui, Masanori Isobe

  • Open Access

    Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial

    by Kyoko Kikuno, Ryuta Asada, Takuma Ishihara, Ken-Ichirou Morishige, Kenro Chikazawa, Tatsuro Furui, Masanori Isobe

    Introduction Dienogest (DNG) is widely used to manage endometriosis-associated pain; however, long-term data comparing low and standard doses are limited. Therefore, this study aimed to evaluate the efficacy and safety of 48-week DNG treatment (1 mg/day vs. 2 mg/day) in patients with endometriosis-related dysmenorrhea (composite score). Methods In this randomized, open-label, parallel-group, trial, 88 patients with endometriosis were enrolled, all of whom had at least one ovarian endometriotic cyst confirmed by imaging. Other phenotypes of endometriosis, such as deep infiltrating or peritoneal lesions, were not systematically assessed and may have been present. Patients were randomized to receive either 1-mg/day or 2-mg/day DNG. The primary endpoint was the change in menstrual pain measured using a visual analog scale (VAS). Secondary endpoints included changes in the dysmenorrhea score, ovarian endometrioma volume, serum estradiol levels, bone mineral density (BMD), and menopausal symptoms. Results Both groups demonstrated a significant reduction in menstrual pain (VAS). The mean VAS scores decreased by 44.63 and 54.19 mm in the 1-mg and 2-mg groups, respectively. However, the between-group difference (– 9.57 mm; 95% confidence interval: − 22.7 to 3.56) was not above the predefined non-inferiority margin of – 15 mm; thus, non-inferiority of the 1-mg dose could not be confirmed. Improvements in dysmenorrhea scores and endometrioma volume were also observed in both groups, although greater effects were noted in the 2-mg group than in the 1-mg group. Serum estradiol suppression was comparable between the groups, whereas BMD loss was less pronounced in the 1-mg group than in the 2-mg group. Conclusions This study did not demonstrate statistical non-inferiority of 1-mg/day DNG treatment over 2-mg/day DNG treatment for pain relief. These results suggest that the 2-mg/day dose may offer more robust analgesic effects, particularly during the early treatment phase. However, 1-mg/day DNG still showed meaningful symptom improvement with fewer adverse events than 2-mg/day DNG, supporting its potential use in selected patients requiring long-term therapy. Trial Registration Japan Registry of Clinical Trials, trial registration number: jRCTs041210016.


  • Open Access

    Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial

    by Kyoko Kikuno, Ryuta Asada, Takuma Ishihara, Yoshimasa Bomoto, Saki Murase, Yoko Ueda, Tomomi Shiga, Yoh Hayasaki, Tatsuro Furui, Satoko Matsuzaki, et al.

    Background: The treatment of endometriosis includes analgesics, hormone therapy, and surgery. Even after surgical removal of endometriotic lesions, the risk of recurrence remains high once the normal menstrual cycle resumes. Therefore, long-term hormone therapy is essential to prevent recurrence. Among hormonal treatments, low-dose estrogen progestin preparations are not recommended for patients older than 40 years due to the increased risk of thrombotic side effects. In contrast, dienogest does not carry a thrombotic risk, making it a suitable option for older patients. Although dienogest requires long-term administration until menopause in patients with endometriosis, data on its long-term efficacy and potential adverse effects remain limited. In particular, comparative studies assessing the safety and effectiveness of long-term use of dienogest at different doses (1 mg/day vs 2 mg/day) have not been conducted, highlighting the need for further investigation. Objective: The purpose of this study is to investigate the efficacy and the incidence of adverse events of dienogest 1 mg/day after 48 weeks in patients with dysmenorrhea due to endometriosis, compared with dienogest 2 mg/day. Methods: This randomized, open-label, parallel-group, dose-comparison, multicenter trial follows the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 guidelines and is conducted at 6 centers in Japan. Participants are randomly assigned in a 1:1 ratio to receive either dienogest 1 mg/day or 2 mg/day. The drug is administered for 48 weeks, and its therapeutic effects and side effects are evaluated. Hospital visits include the use of questionnaires, vital sign measurements, imaging studies (magnetic resonance imaging and ultrasound), blood tests, and bone density assessments. The primary endpoint is the change in the pain visual analog scale (VAS) score from baseline to 48 weeks. The VAS is a 10 cm horizontal scale where 0 cm represents no pain and 10 cm represents the maximum imaginable pain; participants indicate their pain level on the scale, and the change is analyzed over time. The target sample size is 88, determined with a noninferiority margin based on existing literature. The protocol was approved by the Nagoya City University Hospital Clinical Research Review Board. Findings will be presented at academic conferences and published in peer-reviewed journals. Results: Currently, data collection is ongoing. The first participant was enrolled in August 2021. As of March 22, 2025, a total of 88 participants had been enrolled in this clinical trial. Conclusions: This is the first trial to compare efficacy and safety between 1 mg/day and 2 mg/day of long-term dienogest use in patients with dysmenorrhea caused by endometriosis. Combining diagnostic imaging with patient questionnaires and blood tests allows the determination of efficacy against endometriosis itself. Trial Registration: Japan Registry of Clinical Trials jRCTs041210016; https://jrct.mhlw.go.jp/en-latest-detail/jRCTs041210016 International Registered Report Identifier (IRRID): DERR1-10.2196/66246


  • Open Access

    Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer

    by Mika Okazawa-Sakai, Shunsuke A. Sakai, Ichinosuke Hyodo, Satoshi Horasawa, Kentaro Sawada, Takao Fujisawa, Yasuko Yamamoto, Shogen Boku, Yoh Hayasaki, Masanori Isobe, et al.

    Okazawa-Sakai M, et al. J Gynecol Oncol. 2024 Oct;36:e38. https://doi.org/10.3802/jgo.2025.36.e38


  • Open Access

    Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial (Preprint)

    by Kyoko Kikuno, Ryuta Asada, Takuma Ishihara, Yoshimasa Bomoto, Saki Murase, Yoko Ueda, Tomomi Shiga, Yoh Hayasaki, Tatsuro Furui, Satoko Matsuzaki, et al.

    BACKGROUND The treatment of endometriosis includes analgesics, hormone therapy, and surgery. Even after surgical removal of endometriotic lesions, the risk of recurrence remains high once the normal menstrual cycle resumes. Therefore, long-term hormone therapy is essential to prevent recurrence. Among hormonal treatments, low-dose estrogen progestin preparations are not recommended for patients older than 40 years due to the increased risk of thrombotic side effects. In contrast, dienogest does not carry a thrombotic risk, making it a suitable option for older patients. Although dienogest requires long-term administration until menopause in patients with endometriosis, data on its long-term efficacy and potential adverse effects remain limited. In particular, comparative studies assessing the safety and effectiveness of long-term use of dienogest at different doses (1 mg/day vs 2 mg/day) have not been conducted, highlighting the need for further investigation. OBJECTIVE The purpose of this study is to investigate the efficacy and the incidence of adverse events of dienogest 1 mg/day after 48 weeks in patients with dysmenorrhea due to endometriosis, compared with dienogest 2 mg/day. METHODS This randomized, open-label, parallel-group, dose-comparison, multicenter trial follows the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 guidelines and is conducted at 6 centers in Japan. Participants are randomly assigned in a 1:1 ratio to receive either dienogest 1 mg/day or 2 mg/day. The drug is administered for 48 weeks, and its therapeutic effects and side effects are evaluated. Hospital visits include the use of questionnaires, vital sign measurements, imaging studies (magnetic resonance imaging and ultrasound), blood tests, and bone density assessments. The primary endpoint is the change in the pain visual analog scale (VAS) score from baseline to 48 weeks. The VAS is a 10 cm horizontal scale where 0 cm represents no pain and 10 cm represents the maximum imaginable pain; participants indicate their pain level on the scale, and the change is analyzed over time. The target sample size is 88, determined with a noninferiority margin based on existing literature. The protocol was approved by the Nagoya City University Hospital Clinical Research Review Board. Findings will be presented at academic conferences and published in peer-reviewed journals. RESULTS Currently, data collection is ongoing. The first participant was enrolled in August 2021. As of March 22, 2025, a total of 88 participants had been enrolled in this clinical trial. CONCLUSIONS This is the first trial to compare efficacy and safety between 1 mg/day and 2 mg/day of long-term dienogest use in patients with dysmenorrhea caused by endometriosis. Combining diagnostic imaging with patient questionnaires and blood tests allows the determination of efficacy against endometriosis itself. CLINICALTRIAL Japan Registry of Clinical Trials jRCTs041210016; https://jrct.mhlw.go.jp/en-latest-detail/jRCTs041210016 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/66246